Navigation Links
MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/1/2011

MOUNTAIN VIEW, Calif., March 1, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2010.

The net loss for the fourth quarter ended December 31, 2010 was $13.9 million compared to $13.4 million during the same period in 2009. The net loss for the year ended December 31, 2010 was $54.7 million compared to $9.0 million for the year ended December 31, 2009.   The increase in net loss for the 12 month period was primarily due to collaboration revenue received in 2009, including a one-time upfront payment pursuant to a previous license agreement with AstraZeneca, compared to no collaboration revenue in 2010.

MAP Pharmaceuticals had cash and cash equivalents of $76.0 million as of December 31, 2010, compared to $65.8 million as of December 31, 2009.  This does not include the $60.0 million upfront payment the Company received in February 2011 pursuant to its collaboration agreement with Allergan, Inc.

"With a strategic collaboration in place, and all of our clinical trials complete, we look forward to submitting the NDA for LEVADEX in the first half of 2011 and, if approved by the FDA, moving closer to our goal of bringing a new acute treatment option to the migraine market," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "We are very proud of our accomplishments over the past year, and we remain dedicated to our goal of bringing LEVADEX to many of the approximately 30 million American migraine sufferers, including those who have not been successfully treated with currently available therapies."

2010 and 2011 Year-to-Date Accomplishments

LEVADEX™ Clinical Program

  • Announced that a second Phase 3 efficacy trial would not be required for the LEVADEX New Drug Application (NDA) submission.

  • '/>"/>

  • SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
    3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
    4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
    5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
    6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
    7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
    8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
    9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
    10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
    11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... , Nueva Jersey , 22 de enero de ... Biomedical Research abre hoy su llamada a nominaciones para ... investigación científica ha hecho, o tiene el potencial para ... humana. Las nominaciones se aceptarán hasta el 15 de ...
    (Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
    (Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), a ... today that the Company closed its previously announced ... Jack W. Schuler , Birchview Fund LLC ... million, before offering expenses.  The proceeds will be ...
    (Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
    Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
    ... 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" ... Phase II study of intravenous REOLYSIN(R) in patients with ... at the 15th Annual Connective Tissue Oncology Society Meeting ... 7th. The poster presentation, entitled "A Phase II Study ...
    ... . Fuel economy ratings for the new ... www.fueleconomy.gov web site, which Oak Ridge National Laboratory developed ... U.S. Environmental Protection Agency. Nine of the top 10 vehicles ... by the Toyota Prius (51 MPG city; 48 highway). "This ...
    ... , PARSIPPANY, N.J., Nov. 5 DSM Pharmaceutical Products ... with Galenix, Saint Jean D,Illac, France, where DSM will ... commercial products on a global basis. , DSM and ... drug delivery technologies, based on the strength of Galenix ...
    Cached Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
    (Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
    (Date:12/19/2014)... ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced the addition of ... Market" report to their offering. ... market is estimated to grow at a CAGR of 3.6% ... larger share in this market, Canada ...
    (Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has ... - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally different ... the first time a fingerprint sensor in its product. ...
    Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
    ... WALTHAM, MA April 1, 2011 Avila ... drugs, today announced the publication of a scientific ... titled "The Resurgence of Covalent Drugs" ( www.nature.com/reviews/drugdisc , ... discusses the broad opportunities for covalent drugs and how ...
    ... never good for you, but washing that meal down with ... of Guelph study. Researcher Marie-Soleil Beaudoin has discovered not ... eating a high-fat meal, but that the spike doubles after ... to levels similar to those of people at risk for ...
    ... muscle strength. Not only can adults fight the battle ... Golden Years can be a time to get stronger, say experts ... exercise is a great way to increase lean muscle tissue and ... life," says Mark Peterson, Ph.D., a research fellow in the U-M ...
    Cached Biology News:New opportunities for covalent drugs published by Avila scientists 2Got a craving for fast food? Skip the coffee, study says 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 3Older and stronger: Progressive resistance training can build muscle, increase strength as we age 4
    Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
    ... fluorescent and highly photostable FluoSpheres microspheres ... a variety of applications requiring probes ... Unfortunately, protein- and other macromolecule-labeled microspheres ... them to bind to non-target surfaces ...
    SMVT (N-14)...
    ... H2OBIT™ is a fully licensed, high throughput, water ... of up to 24 microplates. This equates to ... A robotic arm rapidly transfers a ... in temperature ramping times that are considerably faster ...
    Biology Products: